key publications
news & press releases
July 2025 – Strategic AI Drug Discovery Collaboration with SandboxAQ
iOncologi entered into a strategic collaboration with SandboxAQ to leverage AI-powered foundational models in the discovery of novel immune targets for personalized cancer therapies, including expansion of the IONC201 and IONC301 platforms.
July 2025 – Breakthrough Research Supports iOncologi’s IONC101 Platform
A landmark study from Dr. Elias Sayour’s lab at the University of Florida, published in Nature Biomedical Engineering, revealed that a novel immunotherapy can broadly activate the immune system to target multiple tumor types—including melanoma, osteosarcoma, and glioma. The approach delivers a powerful “one-two punch,” first priming innate immunity and then overcoming resistance to immune checkpoint inhibitors. iOncologi holds exclusive rights to this groundbreaking technology under its IONC101 platform, positioning the company to translate these findings into a universal, precision-engineered therapy for patients with GBM and other intractable solid tumors.